Mölnlycke Health Care US, LLC introduces Biogel PI Pro-Fit®, a non-latex surgical glove designed to allow for a new level of comfort during surgery while reducing employee and patient health risks and costs.
Designed with a biomechanically optimized former to help prevent hand fatigue during surgery and a synthetic material that feels just as good as latex, 94 percent of surgeons surveyed rated Biogel PI (non-latex) as good as or better than Biogel Latex.
According to a recent study, there are approximately 17 operating room (OR) backtable teardowns per year on average per facility due to undetected latex allergies in patients. With Biogel PI Pro-Fit®, the OR teardown cost risk associated with glove-related patient latex allergies is eliminated.
Additionally over time, healthcare workers can develop latex sensitivity, which can average costs up to $218,000 per employee to treat their latex allergy. Biogel non-latex gloves reduce the risk of workers compensation claims and lost productivity due to staff with glove-related latex allergies being unable to work.
Biogel gloves have statistically significant fewer observed failures than other glove brands, reducing the exposure to pathogens and associated costs of treatment. In an independent observational in-use comparison study, non-Biogel gloves were 3.5 times as likely to fail in-use compared to Biogel surgical gloves.
Source: Mölnlycke Health Care US, LLC Â
Implementing FDA 21 CFR Part 820 & ISO 13485 on Quality System Regulation
August 30th 2024The FDA's 21 CFR Part 820 and ISO 13485 are crucial in regulating medical device quality systems. Harmonizing these standards by 2026 will streamline compliance, improve patient access to devices, and align US regulations with global practices.
The Long-Term Care Chronicles: The Great Mitigators
August 27th 2024Enjoy this first installment of The Long-Term Care Chronicles With Robbie Hilliard, MSN, RN CIC, a column about managing special infection control situations in the long-term care patient population. This installment is about when 2 experts conflict about best care.
Urgent Need for a Paradigm Shift in Infectious Disease Control Amid 2024 Outbreaks
August 26th 2024The 2024 surge in infectious diseases like mpox, measles, and meningitis demands a paradigm shift in control strategies, emphasizing expanded expertise, improved airborne precautions, and rethinking cost-effectiveness in healthcare to prevent future outbreaks and protect public health.
Navigating Infection Prevention Challenges Amid 2024 Outbreaks: Strategies for Success
August 22nd 2024As infectious diseases resurge in 2024, this article explores how IPs can manage outbreaks, allocate resources, use technology for surveillance, and collaborate with senior leaders to ensure business continuity and patient safety in health care settings.